IMCR is a stock that had a lot of big name investors but it could be ready for a deep dive down to $4 as describe on the chart. Not a financial advise.
I bought this NASDAQ:IMCR pullback buy setup on July 5th and got stopped out for 5% gain. It is potentially setting put another pullback buy setup. Previous entry and exit on chart marked as dashes.
Market Phase & Period: Uptrend. February 2022 - November 2022 Description: The trend reached its highs in November 2022 but failed to continue in February 2023, making a double top pattern. The selling pressure observed in February-March 2023 indicates weakness in the bullish momentum, with the price easily reaching $47. April showed some positive movement...
Immunocore Holdings is a commercial-stage T cell receptor biotechnology company working to develop and commercialize transformative medicines for oncology, infectious diseases and autoimmune and inflammation diseases. In a confirmed uptrend, yesterday signaled a good pivot buy where I placed an initial position. I liked the volatility contraction pattern and...
$IMCR potential mini continuation head and shoulders setup.
Investors reacted strongly to the downside on news of the latest trial results, while the companies headline read more bullish. Going to look at this one as potentially oversold - time will tell of course. Could look at a stop limit buy order where if the stock recovers then you can enter the trade, but if it continues to head down then you stay out. Would also...
A recent Biotech IPO that could be putting in the bottom of its IPO base. Breaking its downtrend (red line) and volatility contracting and forming a tight box setup. On focus list for next week. Immunocore Hldgs Plc Ads (IMCR)- DEVELOPS AND MARKETS IMMUNOTHERAPIES WITH T-CELL RECEPTORS TO TREAT CANCER, INFECTIOUS AND AUTOIMMUNE.
IPO intraday trading strategy idea Immunocore is a developer of a novel class of TCR (T cell receptor) bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. The share price is rising and gonna continue this trend today. The demand...